◎ Sugi Atlas

Atlas / Drug / Cediranib

Cediranib

drug
On this page

Also known as Azd-2171AZD2171RecentinZD-2171SID103905340SID137275941Cediranib maleateÊCediranib maleateÂ

Summary

Cediranib (CHEMBL491473) is a phase-3 clinical-stage small molecule (ATC L01EK02) targeting PDGFRA, PDGFRB, and KIT; indicated across 29 conditions including neoplasm and glioblastoma; with CIViC clinical evidence for 2 variant-indication associations (e.g. BRCA1 Mutation in ovarian cancer).

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • ATC class: L01EK02
  • Targets: 8 (PDGFRA, PDGFRB, KIT…)
  • Indications: 29 conditions
  • Clinical trials: 56
  • Precision-oncology evidence (CIViC): 2 variant–indication associations
  • Chemistry: 450.5 Da · C25H27FN4O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL491473
NameCediranib
TypeSmall molecule
Max phase3
FDA approvedno
PubChem CID9933475
ATCL01EK02
Molecular formulaC25H27FN4O3
Molecular weight450.5
InChIKeyXXJWYDDUDKYVKI-UHFFFAOYSA-N

SMILES: CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5

IUPAC name: 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline

Also known as: Azd-2171, AZD-2171, AZD2171, Cediranib, Recentin, ZD-2171, SID103905340, CEDIRANIB, SID137275941, Cediranib maleateÊ, Cediranib maleateÂ

Parent form; salt/anhydrous children: CHEMBL2103798

Patent coverage: 3,303 distinct patent families (9,098 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 6,553 (72%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PDGFRAplatelet derived growth factor receptor alphaInhibition7.446.2%P16234
PDGFRBplatelet derived growth factor receptor betaInhibition8.32.3%P09619
KITKIT proto-oncogene, receptor tyrosine kinaseInhibition8.520.5%P10721
CSF1Rcolony stimulating factor 1 receptorInhibition6.960%P07333
FLT3fms related receptor tyrosine kinase 3Inhibition60.9%P36888
FLT1fms related receptor tyrosine kinase 1Inhibition8.30.1%P17948
KDRkinase insert domain receptorInhibition8.961.1%P35968
FLT4fms related receptor tyrosine kinase 4Inhibition8.520.2%P35916

Broader ChEMBL bioactivity targets: 89 (assay-derived). Sample: Serine/threonine-protein kinase TAO2, Serine/threonine-protein kinase/endoribonuclease IRE1, Receptor tyrosine-protein kinase erbB-2, Tyrosine-protein kinase Fyn, Macrophage colony-stimulating factor 1 receptor, Tyrosine-protein kinase ABL1, Vascular endothelial growth factor receptor 1, Platelet-derived growth factor receptor beta, Mast/stem cell growth factor receptor Kit, Vascular endothelial growth factor receptor 3.

Bioactivity

ChEMBL activities: 194 potent at pChembl ≥ 5 of 203 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
KIT9.57Kd0.27nMCHEMBL_ACT_7567185
KIT9.51Kd0.31nMCHEMBL_ACT_7567187
KIT9.49Kd0.32nMCHEMBL_ACT_7567186
PDGFRB9.49Kd0.32nMCHEMBL_ACT_7567270
KIT9.42Kd0.38nMCHEMBL_ACT_7567180
PDGFRA9.39Kd0.41nMCHEMBL_ACT_7567432
KDR9.3IC500.5nMCHEMBL_ACT_18955285
KDR9.3Ki0.5nMCHEMBL_ACT_27790661
KIT9.27Kd0.54nMCHEMBL_ACT_7567184
FLT19.13Kd0.74nMCHEMBL_ACT_7567248
KDR9IC501nMCHEMBL_ACT_12138565
KDR9IC501nMCHEMBL_ACT_23289709
KDR8.96Kd1.1nMCHEMBL_ACT_7567255
DDR18.77Kd1.7nMCHEMBL_ACT_7567245
KDR8.76IC501.72nMCHEMBL_ACT_25484192
FLT18.67IC502.13nMCHEMBL_ACT_25484155
KDR8.57IC502.7nMCHEMBL_ACT_16394871
FLT48.52IC503nMCHEMBL_ACT_12138564
FLT48.52IC503nMCHEMBL_ACT_23289717
KDR8.4IC504nMCHEMBL_ACT_3595763
FLT48.37Kd4.3nMCHEMBL_ACT_7567249
FLT18.3IC505nMCHEMBL_ACT_12138566
PDGFRB8.3IC505nMCHEMBL_ACT_23289726
FLT18.3IC505nMCHEMBL_ACT_23289735
STK358.27Kd5.4nMCHEMBL_ACT_7569087
RET8.21Kd6.1nMCHEMBL_ACT_7569053
FLT48.2Ki6.31nMCHEMBL_ACT_9635456
RET8.12Kd7.5nMCHEMBL_ACT_7569054
ACSL58.1Kd8nMCHEMBL_ACT_17880028
FLT18.1Ki7.94nMCHEMBL_ACT_9661362

Target pathways

Aggregated over 8 target gene(s): PDGFRA, PDGFRB, KIT, CSF1R, FLT3, FLT1, KDR, FLT4.

Top Reactome pathways

82 total, by targets touching each:

PathwayTargetsGenes
PIP3 activates AKT signaling4FLT3, KIT, PDGFRA, PDGFRB
Constitutive Signaling by Aberrant PI3K in Cancer4FLT3, KIT, PDGFRA, PDGFRB
RAF/MAP kinase cascade4FLT3, KIT, PDGFRA, PDGFRB
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling4FLT3, KIT, PDGFRA, PDGFRB
VEGF binds to VEGFR leading to receptor dimerization3FLT1, FLT4, KDR
Downstream signal transduction2PDGFRA, PDGFRB
Signaling by PDGF2PDGFRA, PDGFRB
Neuropilin interactions with VEGF and VEGFR2FLT1, KDR
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells2FLT4, KDR
PI3K Cascade1FLT3
Developmental Biology1KIT
Signaling by SCF-KIT1KIT
Regulation of KIT signaling1KIT
Signal Transduction1KIT
Disease1KIT
Negative regulation of the PI3K/AKT network1KIT
Generic Transcription Pathway1KIT
Integrin cell surface interactions1KDR
PI3K/AKT Signaling in Cancer1KIT
VEGFA-VEGFR2 Pathway1KDR
Other interleukin signaling1CSF1R
VEGFR2 mediated cell proliferation1KDR
Diseases of signal transduction by growth factor receptors and second messengers1KIT
MAPK family signaling cascades1KIT
MAPK1/MAPK3 signaling1KIT
RNA Polymerase II Transcription1KIT
Gene expression (Transcription)1KIT
Transcriptional Regulation by VENTX1CSF1R
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors1KIT
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors1KIT

Dominant GO biological processes

GO termTargets
cell surface receptor protein tyrosine kinase signaling pathway8
positive regulation of cell population proliferation8
cell migration8
protein autophosphorylation8
protein phosphorylation8
peptidyl-tyrosine phosphorylation7
positive regulation of cell migration7
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction7
positive regulation of ERK1 and ERK2 cascade5
positive regulation of MAPK cascade5
chemotaxis4
angiogenesis4
hemopoiesis4
vascular endothelial growth factor signaling pathway4
regulation of actin cytoskeleton organization3

Indications & clinical

Indications

29 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm3MONDO:0005070EFO:0000616
glioblastoma3MONDO:0018177EFO:0000519
ovarian neoplasm3MONDO:0021068EFO:0003893
ovarian cancer3MONDO:0008170MONDO:0008170
renal cell carcinoma2MONDO:0005086EFO:0000681
breast carcinoma2MONDO:0004989EFO:0000305
prostate adenocarcinoma2MONDO:0005082EFO:0000673
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
biliary tract neoplasm2MONDO:0005304EFO:0003891
alveolar soft part sarcoma2MONDO:0011655EFO:0007143
small cell lung carcinoma2MONDO:0008433EFO:0000702
breast neoplasm2MONDO:0021100MONDO:0007254
metastatic prostate carcinoma2MONDO:0004956EFO:0000196
colorectal neoplasm2MONDO:0005335MONDO:0005575
rectal cancer1MONDO:0006519EFO:1000657
acute myeloid leukemia1MONDO:0018874EFO:0000222
leukemia1MONDO:0005059EFO:0000565
metastatic melanoma1MONDO:0005191EFO:0002617
metastatic neoplasm1MONDO:0024883EFO:0009709
thyroid gland carcinoma1MONDO:0015075EFO:0002892
gastric neoplasm1MONDO:0021085MONDO:0001056
peritoneal neoplasm1MONDO:0006901MONDO:0002087
fallopian tube neoplasm1MONDO:0021092MONDO:0002158
lung neoplasm1MONDO:0021117MONDO:0008903
endometrium neoplasm1MONDO:0021251MONDO:0011962
brain neoplasm1MONDO:0021211EFO:0003833

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 56.

Phase distribution

PhaseTrials
PHASE224
PHASE120
PHASE34
PHASE2/PHASE33
PHASE1/PHASE23
EARLY_PHASE11
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02502266PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTesting the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT00384176PHASE2/PHASE3COMPLETEDFirst Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
NCT00399035PHASE3COMPLETEDCediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
NCT00532194PHASE3UNKNOWNAn RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer
NCT00777153PHASE3COMPLETEDCediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
NCT00939848PHASE2/PHASE3COMPLETEDCediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers
NCT03278717PHASE3UNKNOWNStudy Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients
NCT02484404PHASE1/PHASE2ACTIVE_NOT_RECRUITINGPhase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can…
NCT02893917PHASE2ACTIVE_NOT_RECRUITINGTesting Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
NCT02974621PHASE2ACTIVE_NOT_RECRUITINGCediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
NCT03334617PHASE2ACTIVE_NOT_RECRUITINGPhase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
NCT03851614PHASE2ACTIVE_NOT_RECRUITINGStudy of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
NCT04090567PHASE2RECRUITINGOlaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT04487587PHASE2ACTIVE_NOT_RECRUITINGA Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer
NCT00264004PHASE2COMPLETEDStudy to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
NCT00278889PHASE2COMPLETEDSecond Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
NCT00306891PHASE2COMPLETEDEffect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)
NCT00385203PHASE2COMPLETEDThe Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
NCT00423332PHASE2COMPLETEDCediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
NCT00436956PHASE2COMPLETEDAZD2171 to Treat Prostate Cancer
NCT00454805PHASE2COMPLETEDAZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
NCT00494221PHASE1/PHASE2COMPLETEDA Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
NCT00942877PHASE2COMPLETEDPhase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
NCT01208051PHASE1/PHASE2COMPLETEDCediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
NCT01262612PHASE2TERMINATEDCediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion
NCT01337401PHASE2UNKNOWNA Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)
NCT01391962PHASE2COMPLETEDSunitinib or Cediranib for Alveolar Soft Part Sarcoma
NCT02340611PHASE2COMPLETEDA Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib
NCT02889900PHASE2COMPLETEDEfficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer
NCT02899728PHASE2TERMINATEDOlaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
NCT03117933PHASE2COMPLETEDOlaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
NCT03314740PHASE2COMPLETEDBest Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib
NCT03570437PHASE2UNKNOWNDoes Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?
NCT03741426PHASE2UNKNOWNWIRE - Novel Treatments in Renal Cell Cancer
NCT00750841PHASE1ACTIVE_NOT_RECRUITINGStudy of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
NCT01364051PHASE1ACTIVE_NOT_RECRUITINGCediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
NCT00243347PHASE1COMPLETEDThe Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
NCT00321581PHASE1COMPLETEDAZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia
NCT00475956PHASE1COMPLETEDSafety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
NCT00501605PHASE1COMPLETEDPhase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases

Clinical evidence (CIViC)

Variant × indication × effect (2 predictive associations from 2 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
BRCA1 MutationOvarian CancerSensitivity/ResponseCediranib + OlaparibCIViC BEID1677
BRCA2 MutationOvarian CancerSensitivity/ResponseCediranib + OlaparibCIViC BEID1678

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

250 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
AfatinibChEMBL + PubChemPhase 4 (approved)CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
CrizotinibChEMBL + PubChemPhase 4 (approved)CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
PAZOPANIBChEMBL + PubChemPhase 4 (approved)CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
REGORAFENIBChEMBL + PubChemPhase 4 (approved)CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
AXITINIBChEMBLPhase 4 (approved)CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
FEDRATINIBChEMBLPhase 4 (approved)CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
MIDOSTAURINChEMBLPhase 4 (approved)CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
NINTEDANIBChEMBLPhase 4 (approved)CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
QUIZARTINIBChEMBLPhase 4 (approved)CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
SORAFENIBChEMBLPhase 4 (approved)CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
SUNITINIBChEMBLPhase 4 (approved)CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
VANDETANIBChEMBLPhase 4 (approved)CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
DOVITINIBChEMBLPhase 3CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
LESTAURTINIBChEMBLPhase 3CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
LINIFANIBChEMBLPhase 3CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
MOTESANIBChEMBLPhase 3CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
SEMAXANIBChEMBLPhase 3CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
CENISERTIBChEMBLPhase 2CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
DEFOSBARASERTIBChEMBLPhase 2CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
DORAMAPIMODChEMBLPhase 2CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
FORETINIBChEMBLPhase 2CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
ILORASERTIBChEMBLPhase 2CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
R-406ChEMBLPhase 2CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
RAF-265ChEMBLPhase 2CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
SU-014813ChEMBLPhase 2CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
TANDUTINIBChEMBLPhase 2CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
TOZASERTIBChEMBLPhase 2CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
SelumetinibPubChemApprovedCSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
GefitinibChEMBL + PubChemPhase 4 (approved)CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA
DASATINIBChEMBLPhase 4 (approved)CSF1R, FLT1, FLT3, KDR, KIT, PDGFRA, PDGFRB
ERLOTINIBChEMBLPhase 4 (approved)FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
PEXIDARTINIBChEMBLPhase 4 (approved)CSF1R, FLT1, FLT3, KDR, KIT, PDGFRA, PDGFRB
PONATINIBChEMBLPhase 4 (approved)CSF1R, FLT1, FLT3, KDR, KIT, PDGFRA, PDGFRB
TIVOZANIBChEMBLPhase 4 (approved)FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
BRIVANIBChEMBLPhase 3CSF1R, FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB
VATALANIBChEMBLPhase 3CSF1R, FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB
REBASTINIBChEMBLPhase 2CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA
IdelalisibPubChemApprovedCSF1R, FLT1, FLT3, FLT4, KIT, PDGFRA, PDGFRB
IMATINIBChEMBL + PubChemPhase 4 (approved)CSF1R, FLT3, KDR, KIT, PDGFRA, PDGFRB
ENTRECTINIBChEMBLPhase 4 (approved)CSF1R, FLT1, FLT3, FLT4, KDR, KIT
INFIGRATINIBChEMBLPhase 4 (approved)FLT1, FLT3, FLT4, KDR, KIT, PDGFRA
LENVATINIBChEMBLPhase 4 (approved)FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB
CANERTINIBChEMBLPhase 3FLT1, FLT3, KDR, KIT, PDGFRA, PDGFRB
CEP-32496ChEMBLPhase 2CSF1R, FLT1, FLT3, KDR, KIT, PDGFRB
OSI-632ChEMBLPhase 2FLT1, FLT3, FLT4, KDR, PDGFRA, PDGFRB
BOSUTINIBChEMBLPhase 4 (approved)CSF1R, FLT3, KIT, PDGFRA, PDGFRB
BRIGATINIBChEMBLPhase 4 (approved)CSF1R, FLT3, FLT4, KDR, KIT
CABOZANTINIBChEMBLPhase 4 (approved)FLT1, FLT3, FLT4, KDR, KIT
NILOTINIBChEMBLPhase 4 (approved)CSF1R, FLT3, KIT, PDGFRA, PDGFRB
NINTEDANIB ESYLATEChEMBLPhase 4 (approved)FLT1, FLT4, KDR, PDGFRA, PDGFRB
BARASERTIBChEMBLPhase 3FLT3, KDR, KIT, PDGFRA, PDGFRB
SARACATINIBChEMBLPhase 3FLT3, KDR, KIT, PDGFRA, PDGFRB
VIMSELTINIBChEMBLPhase 3CSF1R, FLT3, KIT, PDGFRA, PDGFRB
AT-9283ChEMBLPhase 2FLT1, FLT3, FLT4, KDR, PDGFRA
BFH-772ChEMBLPhase 2FLT1, FLT4, KDR, KIT, PDGFRB
CEP-11981ChEMBLPhase 2CSF1R, FLT1, FLT3, KDR, PDGFRA
ENMD-2076ChEMBLPhase 2CSF1R, FLT3, KDR, KIT, PDGFRA
MK-2461ChEMBLPhase 2FLT1, FLT3, FLT4, KDR, PDGFRB
SOTULETINIBChEMBLPhase 2CSF1R, FLT3, KIT, PDGFRA, PDGFRB
CERITINIBChEMBLPhase 4 (approved)FLT3, KDR, KIT, PDGFRA

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot